Articles tagged "Immunosuppression"

2016 American Transplant Congress
The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.
D. Fantus,¹ Y. Ono,¹ S. Yokota,¹ C. Komatsu,¹ H. Turnquist,^1,2 A. Thomson.^1,2
¹Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Background: Rapamycin (RAPA), an immunosuppressive agent, inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and mTORC2). While…
2016 American Transplant Congress
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.
M. Henry.
On behalf of the TRANSFORM Investigators, Division of Transplantation Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH.
Purpose: Acute rejection and poor graft function are two major risk factors for allograft failure in kidney transplant (KTx) recipients (KTxR). Although, graft survival and…
2016 American Transplant Congress
An Epidemiological Update of Non-Melanoma Skin Cancer in Immunosuppressed Organ Transplant Recipients with Skin of Color.
C. Shaver, C. Cusack, C. Chung.
Dermatology, Drexel University College of Medicine, Philadelphia, PA.
Introduction:It is predicted by the US census that by year 2050, minorities will become the majority US population. We know skin cancer in patients with…
2016 American Transplant Congress
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.
G. Basso, C. Felipe, A. Ferreira, M. Cristelli, N. Oliveira, T. Sandes-Freitas, J. Mansur, L. Viana, W. Aguiar, E. Campos, M. Gerbasi-DeLima, H. Tedesco-Silva, J. Medina-Pestana.
Hospital do Rim, São Paulo, Brazil.
The purpose of this analysis is to investigate the kinetics of cytomegalovirus (CMV) viral load in kidney transplant recipients receiving tacrolimus (TAC) plus everolimus (EVR)…
2016 American Transplant Congress
Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort.
M. Savic,¹ M. Cruz,² A. Rossi,¹ J. Vella.¹
¹Maine Transplant Program, Maine Medical Center, Portland, ME; ²University of Connecticut, Storrs, CT.
Background: Calcineurin inhibition (CNI) is the single most effective strategy to prevent allograft rejection however tolerability is limited by toxicity. To date, alternate strategies have…
2016 American Transplant Congress
Evaluation of Patient-Reported Nonadherence with Tacrolimus Level Variability in Renal Transplant Recipients.
N. Parrish,¹ T. Kaiser,² A. McCann,¹ J. Aladimi,² J. Harris,³ A. Govil,² B. Abu Jawdeh,² G. Mogilishetty,² R. Alloway,² E. Woodle.²
¹Pharmacy Services, University of Cincinnati Medical Center, Cincinnati, OH; ²Medicine, University of Cincinnati, Cincinnati, OH; ³Transplant, University of Cincinnati Medical Center, Cincinnati, OH.
Medication nonadherence (NA) continues to be a major cause of graft loss post-transplant. Several methods for prospective adherence monitoring have been described including patient interview…
2016 American Transplant Congress
Predictive Model for Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, SC.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to create a model to…
2016 American Transplant Congress
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.
A. Shetty,¹ T. Opas,¹ J. Mathew,¹ V. Mas,² J. Leventhal,¹ N. Sustento-Reodica,¹ L. Gallon.¹
¹Northwestern University, Feinberg School of Medicine, Chicago, IL; ²University of Virginia, Charlottesville, VA.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…
2016 American Transplant Congress
Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Less Cellular Rejection in Lung Transplant Recipients.
C. Ensor, K. Harrigan, R. Venkataramanan, M. Morrell, C. Moore, J. Hayanga, M. Crespo, J. DCunha, A. Zeevi, J. McDyer.
University of Pittsburgh, Pittsburgh, PA.
Purpose: To describe the effect of tacrolimus (FK) time-in-therapeutic range (TTR) on incidence of cellular rejection (ACR) within the first year after lung transplantation (LT).Methods:…
2016 American Transplant Congress
Everolimus/Low Tacrolimus(TAC) Compared to MPA/RegularTAC for Renal Transplantation in the Elderly Recipient – Preliminary Analysis of the nEverOld Trial.
E. David-Neto,¹ F. Agena,¹ F. Ramos,¹ A. Triboni,¹ M. Altona,² V. Coelho,² N. Galante,¹ F. Lemos.¹
¹Kidney Transplant Service, Hospital das Clínicas, University of São Paulo School of Medicine, Sao Paulo, Brazil; ²Geriatric Service, Hospital das Clínicas, University of São Paulo School of Medicine, Sao Paulo, Brazil.
In the last decade, elderly patients (≥60y) have been more frequently listed for renal transplantation. From 2007 to 2014 the percentage of elderly renal transplant…